• Explore /
  • Poster
  • / Updates on phase1b/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus checkpoint inhibitors for the treatment of unresectable stage 3 or 4 melanoma.

Updates on phase1b/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus checkpoint inhibitors for the treatment of unresectable stage 3 or 4 melanoma.

Abstract Poster

Authors

null

Yousef Zakharia

University of Iowa Hospitals and Clinics, Holden Comprehensive Cancer Center, Iowa City, IA

Yousef Zakharia , Joseph J. Drabick , Samir Khleif , Robert R. McWilliams , David Munn , Charles J. Link , Nicholas N. Vahanian , Eugene Kennedy , Montaser F. Shaheen , Olivier Rixe , Mohammed M. Milhem

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research

Sub Track

Immune Checkpoint Inhibitors

Clinical Trial Registration Number

NCT02073123

Citation

J Clin Oncol 34, 2016 (suppl; abstr 3075)

DOI

10.1200/JCO.2016.34.15_suppl.3075

Abstract #

3075

Poster Bd #

397

Abstract Disclosures

Similar Posters

First Author: Zeynep Eroglu

First Author: Eugene Kennedy

First Author: Inge Marie Svane

First Author: Dirk Schadendorf